Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study

J. C. Yao; Nicola Fazio; S. Singh; Roberto Buzzoni; Carlo Carnaghi; Edward M. Wolin; Jiri Tomasek; Markus Raderer; Harald Lahner; M. Voi; Lida Bubuteishvili Pacaud; Nicolas Rouyrre; C. Sachs; J. W. Valle; G. Delle Fave; E. Van Cutsem; M. Tesselaar; Yasuhiro Shimada; D. Y. Oh; Jonathan R. Strosberg; Matthew H. Kulke; M.E. Pavel; Salvatore Tafuto

doi:10.1016/S0140-6736(15)00817-X

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study

J. C. Yao, Nicola Fazio, S. Singh, Roberto Buzzoni, Carlo Carnaghi, Edward M. Wolin, Jiri Tomasek, Markus Raderer, Harald Lahner, M. Voi, Lida Bubuteishvili Pacaud, Nicolas Rouyrre, C. Sachs, J. W. Valle, G. Delle Fave, E. Van Cutsem, M. Tesselaar, Yasuhiro Shimada, D. Y. Oh, Jonathan R. StrosbergMatthew H. Kulke, M.E. Pavel, Salvatore Tafuto

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	968-977
Number of pages	10
Journal	The Lancet
Volume	387
Issue number	10022
DOIs	https://doi.org/10.1016/S0140-6736(15)00817-X
Publication status	Published - 2016

Cite this

Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E. M., ... Tafuto, S. (2016). Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. The Lancet, 387(10022), 968-977. https://doi.org/10.1016/S0140-6736(15)00817-X

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. / Yao, J. C.; Fazio, Nicola; Singh, S.; Buzzoni, Roberto; Carnaghi, Carlo; Wolin, Edward M.; Tomasek, Jiri; Raderer, Markus; Lahner, Harald; Voi, M.; Pacaud, Lida Bubuteishvili; Rouyrre, Nicolas; Sachs, C.; Valle, J. W.; Fave, G. Delle; Van Cutsem, E.; Tesselaar, M.; Shimada, Yasuhiro; Oh, D. Y.; Strosberg, Jonathan R.; Kulke, Matthew H.; Pavel, M.E.; Tafuto, Salvatore.

In: The Lancet, Vol. 387, No. 10022, 2016, p. 968-977.

Research output: Contribution to journal › Article

Yao, JC, Fazio, N, Singh, S, Buzzoni, R, Carnaghi, C, Wolin, EM, Tomasek, J, Raderer, M, Lahner, H, Voi, M, Pacaud, LB, Rouyrre, N, Sachs, C, Valle, JW, Fave, GD, Van Cutsem, E, Tesselaar, M, Shimada, Y, Oh, DY, Strosberg, JR, Kulke, MH, Pavel, ME & Tafuto, S 2016, 'Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study', The Lancet, vol. 387, no. 10022, pp. 968-977. https://doi.org/10.1016/S0140-6736(15)00817-X

Yao, J. C. ; Fazio, Nicola ; Singh, S. ; Buzzoni, Roberto ; Carnaghi, Carlo ; Wolin, Edward M. ; Tomasek, Jiri ; Raderer, Markus ; Lahner, Harald ; Voi, M. ; Pacaud, Lida Bubuteishvili ; Rouyrre, Nicolas ; Sachs, C. ; Valle, J. W. ; Fave, G. Delle ; Van Cutsem, E. ; Tesselaar, M. ; Shimada, Yasuhiro ; Oh, D. Y. ; Strosberg, Jonathan R. ; Kulke, Matthew H. ; Pavel, M.E. ; Tafuto, Salvatore. / Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. In: The Lancet. 2016 ; Vol. 387, No. 10022. pp. 968-977.

@article{ec723e072f294b9fbfe88be4d5cc56dd,

title = "Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study",

author = "Yao, {J. C.} and Nicola Fazio and S. Singh and Roberto Buzzoni and Carlo Carnaghi and Wolin, {Edward M.} and Jiri Tomasek and Markus Raderer and Harald Lahner and M. Voi and Pacaud, {Lida Bubuteishvili} and Nicolas Rouyrre and C. Sachs and Valle, {J. W.} and Fave, {G. Delle} and {Van Cutsem}, E. and M. Tesselaar and Yasuhiro Shimada and Oh, {D. Y.} and Strosberg, {Jonathan R.} and Kulke, {Matthew H.} and M.E. Pavel and Salvatore Tafuto",

note = "Cited By :70 Export Date: 13 March 2017",

year = "2016",

doi = "10.1016/S0140-6736(15)00817-X",

language = "English",

volume = "387",

pages = "968--977",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Lancet Publishing Group",

number = "10022",

}

TY - JOUR

T1 - Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study

AU - Yao, J. C.

AU - Fazio, Nicola

AU - Singh, S.

AU - Buzzoni, Roberto

AU - Carnaghi, Carlo

AU - Wolin, Edward M.

AU - Tomasek, Jiri

AU - Raderer, Markus

AU - Lahner, Harald

AU - Voi, M.

AU - Pacaud, Lida Bubuteishvili

AU - Rouyrre, Nicolas

AU - Sachs, C.

AU - Valle, J. W.

AU - Fave, G. Delle

AU - Van Cutsem, E.

AU - Tesselaar, M.

AU - Shimada, Yasuhiro

AU - Oh, D. Y.

AU - Strosberg, Jonathan R.

AU - Kulke, Matthew H.

AU - Pavel, M.E.

AU - Tafuto, Salvatore

N1 - Cited By :70 Export Date: 13 March 2017

PY - 2016

Y1 - 2016

U2 - 10.1016/S0140-6736(15)00817-X

DO - 10.1016/S0140-6736(15)00817-X

M3 - Article

VL - 387

SP - 968

EP - 977

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10022

ER -

Access to Document

10.1016/S0140-6736(15)00817-X

https://www.scopus.com/inward/record.uri?eid=2-s2.0-84960112967&doi=10.1016%2fS0140-6736%2815%2900817-X&partnerID=40&md5=5c0aaa4aeb18e5c2b705f42e3ab724e3